HydroxyTyrosol / p65 Cancer Research Results

HT, HydroxyTyrosol: Click to Expand ⟱
Features:

Hydroxytyrosol (HT; 3,4-dihydroxyphenylethanol) = phenolic compound from extra-virgin olive oil (EVOO) and olives; also formed from oleuropein metabolism. Small, water-soluble catechol with high antioxidant capacity.
Primary mechanisms (conceptual rank):
1) Direct ROS scavenging + lipid peroxidation inhibition (membrane protection).
2) NRF2 activation → endogenous antioxidant enzymes (HO-1, NQO1, GCLC).
3) Anti-inflammatory modulation (↓ NF-κB, ↓ COX-2, ↓ iNOS).
4) Mitochondrial protection / biogenesis support (model-dependent; PGC-1α linkage reported).
5) Anti-proliferative / pro-apoptotic signaling in cancer (dose- and model-dependent).
PK / bioavailability: well absorbed; rapid phase II metabolism (glucuronide/sulfate conjugates); short plasma half-life; free aglycone concentrations modest vs many in-vitro studies.
In-vitro vs systemic exposure: many cell studies use ≥10–100 µM; typical dietary/EVOO intake yields lower transient plasma levels (conjugated forms predominate).
Clinical evidence status: strongest data in cardiometabolic/vascular endpoints; oncology evidence largely preclinical; neuroprotection mechanistically plausible with limited RCT data.

Hydroxytyrosol is mostly only available from olive oil and leaves, but is available as a common supplement.
Hydroxytyrosol & oleuropein show the most consistent direct anti-CSC activity in multiple models (breast, colon, prostate).
Hydroxytyrosol is potent against CSC phenotypes.

Mechanisms:
-Blocks EMT, reducing transition into CSC-like states
-Inhibits Notch signaling
-Reduces CD44+ / CD24– CSC markers
-Inhibits hypoxia-driven stemness (HIF-1α suppression)

Hydroxytyrosol is especially active in:
-Breast CSCs
-Melanoma CSC-like cells
-Gastric CSC models

Hydroxytyrosol (HT) — Cancer-Relevant Pathways

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 ROS tone / lipid peroxidation ↓ (low–mod dose); ↑ (high concentration only) ↓ P→R Antioxidant; membrane protection Catechol scavenger; at higher concentrations may induce pro-oxidant stress in tumors (model-dependent).
2 NRF2 axis ↑ (context-dependent) ↑ R→G Endogenous antioxidant induction ↑ HO-1/NQO1; protective in normal tissues; could support tumor stress resistance (context-dependent).
3 NF-κB / COX-2 inflammation ↓ ↓ R→G Anti-inflammatory Reduces pro-tumor inflammatory signaling; consistent with Mediterranean diet data.
4 Mitochondrial function ↔ / ↓ proliferation (model-dependent) ↑ (protective) R→G Bioenergetic stabilization Reported support of mitochondrial integrity in normal cells; may impair cancer cell proliferation via metabolic stress.
5 Apoptosis (caspase activation) ↑ (high concentration only) ↔ / ↓ R→G Pro-apoptotic in select tumors Observed at supra-physiologic exposures in vitro.
6 Ferroptosis axis ↓ (anti-lipid-ROS bias) ↓ P→R Inhibits lipid oxidation Strong antioxidant property may counter ferroptotic strategies (context-dependent).
7 Clinical Translation Constraint — — — Exposure limitations Rapid metabolism; plasma free HT lower than many in-vitro doses; best considered dietary adjunct.

TSF Legend: P: 0–30 min | R: 30 min–3 hr | G: >3 hr

Hydroxytyrosol (HT) — Cancer Stemness / EMT Axis (Addendum)

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 EMT (Epithelial–Mesenchymal Transition) ↓ (model-/dose-dependent) ↔ R→G Reduces EMT-associated transcription (e.g., Snail, Twist) Reported attenuation of mesenchymal phenotype; relevance strongest in breast and melanoma models; mostly in-vitro.
2 CSC markers (CD44+/CD24–) ↓ (model-dependent) ↔ G Reduces stemness-associated phenotype Observed reduction in CSC-like populations in breast cancer models; requires supra-physiologic exposure in many studies.
3 Notch signaling ↓ (model-dependent) ↔ R→G Stemness pathway inhibition Downregulation of Notch pathway components reported; central to CSC maintenance; not universally replicated across tumor types.
4 HIF-1α / hypoxia-driven stemness ↓ (preclinical) ↔ R→G Suppresses hypoxia adaptation Reduced HIF-1α signaling may attenuate hypoxia-induced CSC traits; data strongest in gastric and breast models.
5 Tumor-type specificity Breast, Melanoma, Gastric (preclinical) — — CSC-like cell sensitivity Evidence largely limited to cell-line and xenograft systems; translational dosing gap remains significant.

TSF Legend: P: 0–30 min | R: 30 min–3 hr | G: >3 hr


Hydroxytyrosol (HT) — Alzheimer’s Disease–Relevant Axes

Rank Pathway / Axis Cells (neurons/glia) TSF Primary Effect Notes / Interpretation
1 Lipid peroxidation / neuronal membrane protection ↓ P Neuroprotective antioxidant Protects against oxidative membrane injury; aligns with AD oxidative stress hypothesis.
2 NRF2 activation ↑ R→G Endogenous antioxidant upregulation Supports neuronal resilience under oxidative stress.
3 Neuroinflammation (NF-κB) ↓ R→G Microglial modulation Reduces pro-inflammatory cytokines in models.
4 Mitochondrial integrity ↑ R→G Bioenergetic stabilization Improves mitochondrial function in neuronal models; may reduce apoptotic susceptibility.
5 Aβ toxicity modulation ↓ (preclinical) G Reduces amyloid-induced oxidative injury Animal/cell evidence; limited direct human AD trials.
6 Clinical Translation Constraint — — Dietary-level evidence Human data strongest for Mediterranean diet patterns; isolated HT supplementation lacks large AD RCTs.

TSF Legend: P: 0–30 min | R: 30 min–3 hr | G: >3 hr
p65, RelA: Click to Expand ⟱
Source:
Type:
P65, also known as RelA, is a subunit of the NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) transcription factor complex. NF-κB plays a crucial role in regulating immune response, inflammation, and cell survival.
Due to its role in cancer progression, p65 and the NF-κB pathway are considered potential therapeutic targets. Inhibitors of NF-κB signaling are being explored in preclinical and clinical studies as potential cancer treatments.
Many studies have reported that p65 is overexpressed in various types of cancers, including breast, prostate, lung, and colorectal cancers.
In some cancers, elevated p65 levels correlate with higher grades of tumors and advanced stages of disease.

"RELA proto-oncogene, NF-κB subunit." It encodes the p65 protein, which is a central component of the NF‑κB transcription factor complex.
-Chronic activation of RELA and the NF‑κB pathway is frequently associated with cancer progression, promoting inflammation-driven tumorigenesis, chemoresistance, and metastasis.
-RELA interacts with other oncogenic signaling networks (for example, STAT3 and MAPK pathways), further integrating environmental signals that favor cancer progression.

RELA (p65) is a critical subunit of the NF‑κB transcription factor complex, involved in the regulation of genes that control inflammation, cell survival, and proliferation. In the context of cancer, aberrant activation and overexpression of RELA are frequently associated with aggressive tumor behavior, therapy resistance, and poorer patient outcomes in cancers such as breast, lung, colorectal, and pancreatic cancers, among others.

RELA emerges as a potential key contributor to the suppression of glycolysis, mitochondrial respiration, and ATP production in cancer cells. (RELA knockdown signifcantly reduced the tumorigenic.
potential of various pancreatic cancer cell lines).
Scientific Papers found: Click to Expand⟱
4643- OLE,  HT,    Use of Oleuropein and Hydroxytyrosol for Cancer Prevention and Treatment: Considerations about How Bioavailability and Metabolism Impact Their Adoption in Clinical Routine
- Review, Var, NA
TumCCA↑, Apoptosis↑, ER Stress↑, UPR↑, CHOP↑, ROS↑, Bcl-2↓, NOX4↑, Hif1a↓, MMP2↓, MMP↓, VEGF↓, Akt↓, NF-kB↓, p65↓, SIRT3↓, mTOR↓, Catalase↓, SOD2↓, FASN↓, STAT3↓, HDAC2↓, HDAC3↓, BAD↑, BAX↑, Bak↑, Casp3↑, Casp9↑, PARP↑, P53↑, P21↑, p27↑, Half-Life↝, BioAv↓, BioAv↓, selectivity↑, RadioS↑, *ROS↓, *GSH↑, *MDA↓, *SOD↑, *Catalase↑, *NRF2↑, *chemoP↑, *Inflam↓, PPARγ↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Catalase↓, 1,   NOX4↑, 1,   ROS↑, 1,   SIRT3↓, 1,   SOD2↓, 1,  

Mitochondria & Bioenergetics ⓘ

MMP↓, 1,  

Core Metabolism/Glycolysis ⓘ

FASN↓, 1,   PPARγ↑, 1,  

Cell Death ⓘ

Akt↓, 1,   Apoptosis↑, 1,   BAD↑, 1,   Bak↑, 1,   BAX↑, 1,   Bcl-2↓, 1,   Casp3↑, 1,   Casp9↑, 1,   p27↑, 1,  

Protein Folding & ER Stress ⓘ

CHOP↑, 1,   ER Stress↑, 1,   UPR↑, 1,  

DNA Damage & Repair ⓘ

P53↑, 1,   PARP↑, 1,  

Cell Cycle & Senescence ⓘ

P21↑, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

HDAC2↓, 1,   HDAC3↓, 1,   mTOR↓, 1,   STAT3↓, 1,  

Migration ⓘ

MMP2↓, 1,  

Angiogenesis & Vasculature ⓘ

Hif1a↓, 1,   VEGF↓, 1,  

Immune & Inflammatory Signaling ⓘ

NF-kB↓, 1,   p65↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 2,   Half-Life↝, 1,   RadioS↑, 1,   selectivity↑, 1,  
Total Targets: 37

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

Catalase↑, 1,   GSH↑, 1,   MDA↓, 1,   NRF2↑, 1,   ROS↓, 1,   SOD↑, 1,  

Immune & Inflammatory Signaling ⓘ

Inflam↓, 1,  

Functional Outcomes ⓘ

chemoP↑, 1,  
Total Targets: 8

Scientific Paper Hit Count for: p65, RelA
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:376  Target#:238  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page